文献速递传染病防控与疫情报告免疫规划

2023年澳大利亚儿童SARS-CoV-2原始株与Omicron变异株免疫力血清流行病学研究

SARS-CoV-2 Ancestral and Omicron variant immunity in Australian children in 2023, a seroprevalence study.
PubMed 文献 · Vaccine · 2026-05-17

1065名儿童中,原始株S抗体调整血清阳性率为93.1%,N抗体为79.8%,提示几乎所有儿童已有感染证据。S抗体几何平均浓度随年龄和疫苗接种增加,未接种1岁以上儿童对Omicron BA.5的GMC最高,提示变异株特异性免疫印迹。

要点

  • 2023年底澳大利亚儿童SARS-CoV-2感染血清阳性率极高,S抗体达93.1%。
  • 6-11月龄婴儿血清阳性率最低,S抗体69.5%、N抗体35.2%。
  • S抗体浓度随年龄和疫苗接种增加,未接种年长儿童对BA.5的GMC最高。

核心结论

  • 至2023年底,近所有受试儿童有SARS-CoV-2感染血清学证据,对原始株和Omicron BA.5刺突蛋白抗体浓度最高,提示变异株特异性免疫印迹。

研究设计与样本

  • 采用多水平回归与后分层法估计粗率和调整血清阳性率,并计算S和N抗体的几何平均浓度(GMC)。

主要发现

  • 1065名儿童中,原始株S抗体调整血清阳性率为93.1%(95% CrI 91.4-94.5),N抗体为79.8%(95% CrI 77.1-82.2)。
  • 血清阳性率在各辖区、社会经济五分位和偏远类别均高,6-11月龄婴儿最低:S抗体69.5%(95% CrI 54.7-81.8),N抗体35.2%(95% CrI 21.1-49.1)。
  • 对9种SARS-CoV-2刺突变异株的GMC均高,且随年龄和疫苗接种增加;原始株S抗体GMC在完成两剂疫苗的儿童中最高,未接种1岁以上儿童对Omicron BA.5的GMC最高。

临床怎么用

  • 儿童SARS-CoV-2血清阳性率极高,临床评估时应考虑既往感染和变异株特异性免疫印迹对抗体反应的影响。
  • 婴儿血清阳性率较低,可能是预防和监测的重点人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The emergence of the SARS-CoV-2 Omicron variant in late 2021 led to widespread infection in Australian children, many unvaccinated. The breadth and magnitude of antibody responses to SARS-CoV-2 variant infections and vaccination in children remain incompletely understood. We aimed to estimate seroprevalence against SARS-CoV-2 spike (S) and nucleocapsid (N) antigens and explore antibody kinetics, focusing on Omicron subvariants. METHODS: Between 1 November and 7 December 2023, blood samples were collected from children aged 0-16 years undergoing anaesthetic procedures at eight tertiary paediatric hospitals. SARS-CoV-2 antibodies to ancestral spike and nucleocapsid protein and eight Omicron spike proteins were tested. Crude and adjusted seroprevalence estimates derived using multilevel regression and poststratification were obtained. Geometric mean concentrations (GMCs) were calculated for S- and N- antibodies and analysed by age and vaccination status. RESULTS: Of 1065 children tested, adjusted seroprevalence to ancestral S-antibody was 93.1% (95% CrI, 91.4-94.5) and N-antibody was 79.8% (77.1-82.2). Seroprevalence was high across jurisdictions, socioeconomic quintiles, and remoteness categories, and lowest in infants aged 6-11 months (S-antibody, 69.5% [95% CrI: 54.7-81.8] and N-antibody 35.2% [95% CrI: 21.1-49.1]). GMCs to nine distinct SARS-CoV-2 spike variants were uniformly high and increased with age and vaccination. GMC to ancestral S-antibody was highest in two-dose vaccinated children while unvaccinated children aged >1 year had highest GMC to Omicron BA.5. DISCUSSION: By late 2023, nearly all participants had serological evidence of SARS-CoV-2 infection, with highest concentrations to ancestral strain and Omicron BA.5 spike proteins, suggesting variant-specific immune imprinting.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Koirala A, Prasad SA, Tjiam MC, et al. SARS-CoV-2 Ancestral and Omicron variant immunity in Australian children in 2023, a seroprevalence study. Vaccine. 2026. PMID: 42143953. doi:10.1016/j.vaccine.2026.128705

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。